Niagen®+ for Healthy Aging

Overseen By JESSIE HAWKINS, PhD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Nutraceuticals Research Institute

Must not be taking: NAD+ supplements

Disqualifiers: Seizure disorder, Diabetes, Heart disease, others

Compensation: Varies

Number of Visits: Unknown

Duration: 10 days

70 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot start any new medications or supplements within 60 days before the study begins.

Is Niagen®+ safe for humans?

The available research does not provide specific safety data for Niagen®+ in humans, but it highlights the importance of evaluating safety and efficacy in aging-related treatments. ^{1 2 3 4 5}

How does the treatment Niagen®+ differ from other treatments for healthy aging?

Niagen®+ is unique because it may include components that support healthy aging by potentially enhancing neuronal function and reducing age-related cognitive decline, similar to the benefits seen with diets rich in antioxidants and anti-inflammatory compounds found in fruits and vegetables. ^{6 7 8 9 10}

What is the purpose of this trial?

This study evaluates the subjective effects of injection administration of NR on healthy adult populations.

Eligibility Criteria

Adults aged 40-65 with a BMI of 25-34.9, living within 100 miles of the study site, and leading a sedentary lifestyle can join this trial. They must be in good health, not use NAD+ supplements recently, and agree to lifestyle rules and contraception if applicable. Those with chronic illnesses or recent significant weight changes cannot participate.

Inclusion Criteria

Agreement to adhere to Lifestyle Considerations throughout study duration

Provision of signed and dated informed consent form

Lives within 100 miles of the NRI study site

Exclusion Criteria

Out of range phosphate levels at baseline

Positive COVID-19 test within 30 days of the study period

ANY chronic illness (pre-disease state acceptable)

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive injections of NR or NAD+ via various routes to assess absorption and tolerability

10 days

Multiple visits for injections and assessments

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Niagen®+

Trial Overview The trial is testing how well the body absorbs Niagen®+, compared to NAD+, when injected into healthy adults. It looks at tolerability and subjective effects on aging-related fatigue by randomly assigning participants to receive either Niagen®, NAD+, or a placebo.

Participant Groups

Group I: NR via subcutaneous injection Experimental Treatment 1 Intervention

100mg NR 2ml bacteriostatic water via subcutaneous (SQ) injection

Group II: NR via IV push Experimental Treatment 1 Intervention

100mg NAD+ 2ml bacteriostatic water via intravenous push (IVP) injection

Group III: NR via IM injection Experimental Treatment 1 Intervention

100mg NR 2ml bacteriostatic water via intramuscular (IM) injection

Group IV: NAD+ via IM injection Active Control 1 Intervention

100mg NAD+ in 2ml bacteriostatic water via intramuscular (IM) injection

Group V: NAD+ via subcutaneous injection Active Control 1 Intervention

100mg NAD+ in 2ml bacteriostatic water via subcutaneous (SQ) injection

Group VI: NAD+ via IV push Active Control 1 Intervention

100mg NAD+ 2ml bacteriostatic water via intravenous push (IVP) injection

Group VII: placebo via IM injection Placebo Group 1 Intervention

2ml bacteriostatic water via intramuscular (IM) injection

Group VIII: placebo via subcutaneous injection Placebo Group 1 Intervention

2ml bacteriostatic water via subcutaneous (SQ) injection

Group IX: placebo via IV push Placebo Group 1 Intervention

2ml bacteriostatic water via intravenous push (IVP) injection

Who Is Running the Clinical Trial?

Nutraceuticals Research Institute

Lead Sponsor

Trials

19

Recruited

3,700+

ChromaDex, Inc.

Industry Sponsor

Trials

8

Recruited

400+

References

1. England pubmed.ncbi.nlm.nih.gov

The road ahead for health and lifespan interventions. [2021]

2. Switzerland pubmed.ncbi.nlm.nih.gov

Optimising the selection of outcomes for healthy ageing trials: a mixed methods study. [2023]

3. United States pubmed.ncbi.nlm.nih.gov

Geroprotectors.org: a new, structured and curated database of current therapeutic interventions in aging and age-related disease. [2023]

4. Germany pubmed.ncbi.nlm.nih.gov

Chemical screen identifies a geroprotective role of quercetin in premature aging. [2020]

5. England pubmed.ncbi.nlm.nih.gov

Dietary scores at midlife and healthy ageing in a French prospective cohort. [2018]

6. United States pubmed.ncbi.nlm.nih.gov

Nutrition, brain aging, and neurodegeneration. [2022]

7. Ireland pubmed.ncbi.nlm.nih.gov

Maintenance of a healthy trajectory of the intestinal microbiome during aging: a dietary approach. [2022]

8. Germany pubmed.ncbi.nlm.nih.gov

The andrologist's contribution to a better life for ageing men: part 2. [2016]

9. United States pubmed.ncbi.nlm.nih.gov

Fruit polyphenols and their effects on neuronal signaling and behavior in senescence. [2017]

10. Netherlands pubmed.ncbi.nlm.nih.gov

Twenty years of progress in biogerontology research. [2021]